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1. Introduction
  Rheumatoid arthritis (RA) is the common clinical disease 
with attack in arthrosis of arms and legs; it is a autoimmune 
disease with joint synovitis as the major clinical 
characteristic[1-3]. RA mainly invades joint synovium, 
and it can also influence visceral organs like heart, lung, 
kidney, artery and nerve etc. The clinical manifestations 
of RA usually include symmetrical, polyarticular and 
chronic inflammatory lesions; the main pathological 
changes include hyperplasia, expansion and hyperaemia 
of synoviocytes, inflammatory cell infiltration as well as 
degeneration and proliferation of fibrous tissues etc[4,5]. 
Currently, the pathogenesis of RA has not been completely 
clinically confirmed yet. Some scholars believe that the 
attack of RA is related to infection, immunoregulation and 
heredity[6-9]. In addition, some other researchers think 
Objective: To investigate the therapeutic effect of the intervention treatment with different 
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Group C, Group D, Group E with 10 rats in each group. Injection of Freund’s complete adjuvant 
was employed to establish adjuvant-induced arthritis model in rats. Group A was model group; 
after model establishment, rats were treated with 20 mL normal saline as placebo (ip.). Rats 
in Group B were treated with 8 mg/kg cyclophosphamide (ip.). Rats in Group C, D and E were 
intraperitoneally injected with 30 mg/kg, 100 mg/kg and 300 mg/kg Captopril respectively. Rats in 
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each group rats were compared for the hind legs arthrocele. Right ankle tissues of rats were 
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in other 4 groups (P<0.05). TNF-毩content in serum of Group B rats was significantly lower 
compared with that of rats in Groups C, D and E. The highest TNF-毩content in serum of rats 
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showed significant activities against tardive arthrocele; the degree of ankle arthrocele in rats of 
these three groups was lower than that of Group A rats (P<0.01). Histological observation showed 
that large amount of inflammatory cells and plasmocyte infiltration was found in ankle synovial 
tissues of Group A rats. Relief of hyperaemia and edema of right ankle synovial tissues as well 
as significant decrease in synoviocyte layer hyperplasia, intra-articular inflammatory cells 
infiltration and cartilago articularis damage degree etc. were observed in Groups B, C, D and E. 
Conclusions: Intervention treatment with Captopril can effectively reduce the TNF-毩content 
in serum of rheumatoid arthritis rats and inhibit the generation of inflammatory factors, so as to 
achieve the therapeutic effect.
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that the attack of RA is related to immunodisorder of body 
fluid[10-12]. The immunodisorder of body fluid causes mass 
generation of immune complexes, such as rheumatoid factor, 
which damage the hyaline cartilage and fiber, leading to 
the destruction of cartilage and bone. Therefore, cytokines 
play an important role during the pathogenic process 
of RA. A study verified that TNF2A plays a particularly 
important role in different stages of RA synovitis as well as 
development of articular substrate degeneration[13]. Besides, 
TNF2A is considered as the key cytokine to regulate the 
express of other proinflammartory cytokines during the 
course of RA. Captopril is an angiotensin converting enzyme 
inhibitor with effects of reducing bradykinin degradation 
and inhibiting synthesis of angiotensin II. Captopril can 
significantly alleviate tissue edema and inflammatory 
exudation, possessing anti-inflammatory and anti-fibrosis 
activities. It is proven in a study that Captopril have, to 
some extent, therapeutic effects on rheumatoid disease. In 
order to investigate the therapeutic effects and mechanism 
of Captopril against rheumatoid arthritis, the present study 
used Wistar rats to establish RA model and give intervention 
treatment with Captopril. The results are reported as follows.
2. Materials and methods
2.1. Experimental animals
  50 healthy adult Wistar rats of clean grade with either 
sex, weighting 150-200 g with average weight of (175依12) g, 
from experimental center of Hebei Medical University were 
selected. Rats had access to water ad arbitrium and treated 
with class II feeding. Handle of experimental animals during 
the experiments strictly followed the relevant provisions 
of Regulation for the Administration of Affairs Concerning 
Experimental Animals.
2.2. Apparatus and reagents
  Olympus optical microscope and biomicroscope (Olympus, 
Japan) were used. Electronic analytical balances produced by 
Shanghai Balance Instrument, LD5-10 centrifuge produced 
by Beijing Centrifuge Factory and microplate reader 
(TECAN, Austria) were used. Tumor putrescence factor--毩
kit was purchased from Boster Biological Technology., LTD, 
and Captopril was purchased from Guangzhou Bai Yun Shan 
Pharmaceutical General Factory. 25% Urethane was provided 
by Beijing Zhongshan Golden Bridge Biotechnology Co., 
LTD; sodium carboxymethylcellulose and cyclophosphamide 
were provided by Shanghai Chemical Reagent Factory 
and Freund’s adjuvant was provided by Beijing Guoding 
Biotechnology Co., LTD.
2.3. Model establishment
  Injection of Freund’s adjuvant was employed to establish 
RA model. Rats were injected with 0.05 mL Freund’s 
adjuvant by microsyringe in the posterior part of right hind 
limb. After injection, rats cannot walk by right hind feet, 
behaving restlessly. After 18 h, evident ankle swelling of 
right hind limb was observed; rats shown slow walk and 
decrease in taking food. Three days after injection, ankle 
swelling of right hind limb was alleviated, but became 
serious on Day 8, manifesting ankle swelling of left hind 
limb which was not injected with Freund’s adjuvant. Around 
10 days later, multi-arthritis was observed in the rats, 
indicating the successful establishment of RA model.   
2.4. Animal grouping
  Fifty Wistar rats were randomly divided into 5 groups, 
namely, Group A, Group B, Group C, Group D, Group E with 
10 rats in each group. Group A was model group; after model 
establishment, rats were treated with 20 mL normal saline 
as placebo (ip.). Rats in Group B were treated with 8 mg/
kg cyclophosphamide (ip.). Rats in Group C, D and E were 
intraperitoneally injected with 30 mg/kg, 100 mg/kg and 
300 mg/kg Captopril respectively. Rats in each group were 
subjected to continuous treatment for 3 weeks.
2.5. Observation of the experimental animals
  Displacement of left and right ankle of rats in each group 
was measured one hour before model establishment, 
18 h after modeling and every other day after model 
establishment; the difference of displacement before and 
after inflammation indicates the degree of articular swelling. 
After experiments, rats were sacrificed by injecting with 2% 
pentobarbital sodium (ip.). Eyeballs of rats were excised and 
blood was collected. TNF-毩content in serum were detected 
using ELISA, and detection procedures were performed 
strictly according to the operation instruction of reagents. 
Right ankle tissues of rats were collected to prepare section, 
stained by HE and microscopically observed for pathologic 
changes such as ankle synovial tissues proliferation, 
inflammatory cellular infiltration, destruction of cartilage 
and bone, and tissue edema around arthrosis. 
2.6. Statistical analysis
  The data obtained were analyzed by statistical software 
SPSS 17.0. Data were expressed as mean依SD. One-way 
analysis of variance was employed for comparison among 
groups. t-test was used and P<0.05 was considered to be 
statistically significant.  
3. Results
3.1. Comparison of arthrocele in rats of each group at 
different time points   
  18 h after injection of adjuvant, evident ankle swelling 
was observed in Group A rats. Three days after injection, 
swelling was alleviated, but became serious on Day 8, and 
degree of arthrocele increased with the expansion of time. 
No arthrocele was observed in rats of Groups B, C, D and E 
3 days prior to treatment, showing no statistical difference 
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compared with rats in Group A (P>0.05). However, 10 days 
after treatment, arthrocele in rats of Groups B, C, D and E 
was significantly relieved compared with rats in Group A 
(P<0.05) . There was no statistical difference among Groups 
B, C, D and E regarding arthrocele after treatment (P>0.05) 
(Table 1). 
3.2. Comparison of TNF-毩content in serum of each group 
rats in the early stage of treatment
  TNF-毩content in serum of Groups A, B, C, D and E rats 
at 21 d after modeling was (370.57依45.40), (305.71依26.37), 
(327.67依39.72), (318.71依24.02), and (314.10 依29.18) ng/mL, 
respectively. TNF-毩content in serum of Group A rats was 
significantly higher than that of other 4 group rats (P<0.05). 
TNF-毩content in serum of Group B rats was significantly 
lower than that of Groups C, D and E (P<0.05). Decrease of 
TNF-毩content in serum of Groups C, D and E rats showed a 
dose-dependent manner, namely, the higher dose, the lower 
TNF-毩content in serum.
3.3. Histological changes
  By microscopic observation, large amount of plasmocyte 
and inflammatory cell infiltrations were found in the right 
ankle synovial tissues of Group A rats. Relief of hyperaemia 
and edema of right ankle synovial tissues as well as 
significant decrease in synoviocyte layer hyperplasia, 
intra-articular inflammatory cells infiltration and cartilago 
articularis damage degree etc. were observed in Groups B, 
C, D and E. In regard to Groups C, D and E rats treated with 
Captopril, Group E rats showed the minimum ankle damage, 
followed by Group D, and Group C showed comparatively 
the most serious damage among the Captopril treated groups 
(Figure 1).     
Group A                                  Group B                                  Group C
Group D                                   Group E
Figure 1. Observation for histological changes (HE, ×400).
Table 1
Comparison of arthrocele in rats of each group at different time points.
Groups n
Degree of arthrocele (mL)
18 h 3 d 8 d 10 d 15 d 21d
GroupA 10 1.04依0.15 1.03依0.06 1.05依0.08 1.07依0.09 1.08依0.16 1.10依0.15
GroupB 10 1.04依0.07 1.00依0.12  0.79依0.10*  0.65依0.06*  0.62依0.11*  0.56依0.12*
GroupC 10 1.04依0.10 1.02依0.11 1.00依0.17   0.78依0.12**  0.72依0.18*  0.70依0.08*
GroupD 10 1.04依0.06 1.02依0.16  0.86依0.11*   0.78依0.06**  0.72依0.14*  0.68依0.11*
GroupE 10 1.03依0.06 1.02依0.15  0.85依0.13*   0.75依0.08**  0.71依0.18*  0.65依0.11*
Note: *P<0.05 compared with Group A.
4. Discussion
  RA, a common clinical disease with morbidity of about 
1% worldwide, is the autoimmune disease characterized 
by disabling multi-joint synovitis[15]. The main pathologic 
change of RA is synovitis, manifesting mass trichoid 
protuberance on the surface of synovial membrane and 
generation of new vessels. Hence pannus is formed, 
damaging the bone and cartilage tissue[16]. The main clinical 
symptoms of RA include articular dyskinesia, swell and 
pain, and morning stiffness etc. During the late stage, RA 
can involve lung, heart, gastrointestinal tract, kidney, 
nervous system and blood system, causing multiple organs 
damage [17]. RA showed significant difference of course of 
disease, severity of disease and prognosis among different 
patients. If RA cannot be treated timely, it will aggravate 
gradually[18]. Therefore, early diagnosis and treatment of 
RA are significant for prognosis of patients. The present 
study adopted injection of Freund’s adjuvant to prepare RA 
model. Observations such as evident swelling of right hind 
limb ankle at 18 h after injection, aggravated swelling 8 days 
later and multiple arthritis observed around 10 days later 
indicate that this method for model establishment is fast and 
effective. 
  Currently, the pathogenesis of RA has not been completely 
clinically confirmed yet, but with the development of 
molecular biological technology, many researchers gradually 
realized the importance of cytokines and T lymphocyte 
subpopulation during the morbidity of RA[19]. A study stated 
that TND2A played a very significant role in the cytokine 
network and development of RA[20]. TNF-毩is the key 
cytokine to regulate the express of other proinflammartory 
cytokines; it resists against TNF-毩antibody and at the 
same time inhibit IL-1, IL-6 and GM-CSF produced by 
synoviocytes, thus reducing the diseased joint inflammatory 
reaction[21-22]. Captopril is an angiotensin converting enzyme 
inhibitor with effects of reducing bradykinin degradation and 
inhibiting synthesis of angiotensin II; it can lower pulmonary 
artery hyperpiesia and prevent pathological reproduction 
of angiocarpy. A study shown that Captopril possesses 
remarkable activities of scavenging oxygen free redicals and 
inhibiting lipid peroxidation etc. It can also reduce vascular 
permeability, tissue edema and inflammatory exudation, 
having anti-inflammatory and anti-fibrosis effects to 
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some extent[23]. Another research confirmed that Captopril 
can effectively decrease the TNF-毩level in RA patients, 
inhibiting their inflammatory reaction[24]. In the present 
study, Groups C, D and E rats were treated with different 
doses of Captopril, and the TNF-毩level was significantly 
lower compared with that of Group A rats (P<0.05). This 
verified that Captopril can indeed effectively decrease 
the TNF-毩level in RA patients, and the effect was dose-
dependent, namely, the higher dose, the lower TNF-毩level 
in serum. Results of the present study showed that the ankle 
swelling of rats treated with Captopril was better than that 
of Group A rats (P<0.05). Histological observation revealed 
relief of hyperaemia and edema of right ankle synovial 
tissues as well as significant decrease in synoviocyte layer 
hyperplasia, cartilago articularis damage degree and intra-
articular inflammatory cells infiltration in rats treated 
with Captopril. The ankle injury of rats with treatment of 
Captopril was significantly alleviated compared with Group 
A rats, indicating the remarkable inhibitory activity of 
Captopril against secondary foot edema in RA rats. Captopril 
can effectively inhibit the arthritic damage, revealing certain 
anti-inflammatory and antirheumatic effects of Captopril. 
The activity of reducing the TNF-毩level in serum may be 
responsible for anti-inflammatory and antirheumatic effects 
exhibited by Captopril. 
    Results of the present study showed that Captopril possess 
evident anti-inflammatory and antirheumatic effects. 
Treatment with Captopril can significantly reduce the 
TNF-毩level in serum of RA rats, therefore inhibiting the 
production of inflammatory factor and decreasing its damage 
to joint.
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